OTCMKTS:NVZMF

Novozymes A/S Competitors

$74.15

+4.20 (+6.00 %)

(As of 05/14/2021 12:14 PM ET)

Add

Compare

Today's Range

$69.83

▼

$74.15

50-Day Range

$61.01

▼

$73.50

52-Week Range

$50.04

▼

$75.38

Volume133 shs

Average Volume1,177 shs

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Novozymes A/S (OTCMKTS:NVZMF) Vs. DDXS, TNGN, ATTBF, ADTX, AGNPF, and LBTSF

Should you be buying NVZMF stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Novozymes A/S, including (DDXS) (DDXS), (TNGN) (TNGN), Abattis Bioceuticals (ATTBF), ADiTx Therapeutics (ADTX), Algernon Pharmaceuticals (AGNPF), and Almirall (LBTSF).

Novozymes A/S vs. (DDXS) Stock

(DDXS) (OTCMKTS:DDXS) and Novozymes A/S (OTCMKTS:NVZMF) are both health technology companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation.

Valuation and Earnings

This table compares (DDXS) and Novozymes A/S's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
(DDXS)	N/A	N/A	N/A	N/A	N/A
Novozymes A/S	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares (DDXS) and Novozymes A/S's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
(DDXS)	N/A	N/A	N/A
Novozymes A/S	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for (DDXS) and Novozymes A/S, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
(DDXS)	0	0	0	0	N/A
Novozymes A/S	0	0	0	0	N/A

Novozymes A/S vs. (TNGN) Stock

Novozymes A/S (OTCMKTS:NVZMF) and (TNGN) (OTCMKTS:TNGN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Novozymes A/S and (TNGN), as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novozymes A/S	0	0	0	0	N/A
(TNGN)	0	0	0	0	N/A

Profitability

This table compares Novozymes A/S and (TNGN)'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Novozymes A/S	N/A	N/A	N/A
(TNGN)	N/A	N/A	N/A

Valuation and Earnings

This table compares Novozymes A/S and (TNGN)'s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novozymes A/S	N/A	N/A	N/A	N/A	N/A
(TNGN)	N/A	N/A	N/A	N/A	N/A

Novozymes A/S vs. Abattis Bioceuticals Stock

Novozymes A/S (OTCMKTS:NVZMF) and Abattis Bioceuticals (OTCMKTS:ATTBF) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, risk, valuation and profitability.

Profitability

This table compares Novozymes A/S and Abattis Bioceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Novozymes A/S	N/A	N/A	N/A
Abattis Bioceuticals	N/A	N/A	N/A

Earnings and Valuation

This table compares Novozymes A/S and Abattis Bioceuticals' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novozymes A/S	N/A	N/A	N/A	N/A	N/A
Abattis Bioceuticals	N/A	N/A	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent recommendations and price targets for Novozymes A/S and Abattis Bioceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novozymes A/S	0	0	0	0	N/A
Abattis Bioceuticals	0	0	0	0	N/A

Novozymes A/S vs. ADiTx Therapeutics Stock

Novozymes A/S (OTCMKTS:NVZMF) and ADiTx Therapeutics (NASDAQ:ADTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, dividends and profitability.

Profitability

This table compares Novozymes A/S and ADiTx Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Novozymes A/S	N/A	N/A	N/A
ADiTx Therapeutics	N/A	N/A	N/A

Valuation and Earnings

This table compares Novozymes A/S and ADiTx Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novozymes A/S	N/A	N/A	N/A	N/A	N/A
ADiTx Therapeutics	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and target prices for Novozymes A/S and ADiTx Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novozymes A/S	0	0	0	0	N/A
ADiTx Therapeutics	0	0	1	0	3.00

Summary

ADiTx Therapeutics beats Novozymes A/S on 1 of the 1 factors compared between the two stocks.

Novozymes A/S vs. Algernon Pharmaceuticals Stock

Novozymes A/S (OTCMKTS:NVZMF) and Algernon Pharmaceuticals (OTCMKTS:AGNPF) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, profitability, valuation and dividends.

Profitability

This table compares Novozymes A/S and Algernon Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Novozymes A/S	N/A	N/A	N/A
Algernon Pharmaceuticals	N/A	N/A	N/A

Valuation & Earnings

This table compares Novozymes A/S and Algernon Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novozymes A/S	N/A	N/A	N/A	N/A	N/A
Algernon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Novozymes A/S and Algernon Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novozymes A/S	0	0	0	0	N/A
Algernon Pharmaceuticals	0	0	0	0	N/A

Novozymes A/S vs. Almirall Stock

Novozymes A/S (OTCMKTS:NVZMF) and Almirall (OTCMKTS:LBTSF) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, profitability, valuation and dividends.

Profitability

This table compares Novozymes A/S and Almirall's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Novozymes A/S	N/A	N/A	N/A
Almirall	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Novozymes A/S and Almirall, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novozymes A/S	0	0	0	0	N/A
Almirall	0	1	1	0	2.50

Valuation & Earnings

This table compares Novozymes A/S and Almirall's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novozymes A/S	N/A	N/A	N/A	N/A	N/A
Almirall	N/A	N/A	N/A	N/A	N/A

Summary

Almirall beats Novozymes A/S on 1 of the 1 factors compared between the two stocks.